Skip to content
DataLookout
Menu

ADAPT Forward2NCT07673627

ADAPT Forward 2 - ISA2 - a Study to Evaluate the Safety, Tolerability and Efficacy of Empasiprubart IV Monotherapy in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis

StatusRecruiting
PhasePhase 2
Sponsorargenx
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 8 versions: 8 with changes below. See every version on ClinicalTrials.gov ↗

  1. Minor Trial sites expanded: 14 → 19 locations
  2. Minor Trial sites expanded: 8 → 14 locations
  3. Minor Trial sites expanded: 4 → 8 locations
  4. Minor Site details revised at 1 of 4 sites
  5. Notable Eligibility criteria expanded, about 7 words
    • Study sites: 3 to 4
    • Secondary endpoints: details revised at 7 of 9 entries
  6. Minor Study sites: 2 to 3v3
  7. Notable Recruitment opened
    • Study sites: 0 to 2
    • Start date changed from estimate of Jun 29, 2026 to Jul 10, 2026
    v2
  8. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Incidence of adverse events and serious adverse events in the DBTP
Timeframe: Up to 12 weeks

Secondary (9)

MG-ADL total score change from baseline at week 12
QMG total score change from baseline at week 12
MG-ADL total score change from baseline over time up to week 12
QMG total score change from baseline over time up to week 12
Proportion of participants reaching MSE at any point by week 12
Show 4 moreShow less
Proportion of participants who have ≥3-point reduction in MG-ADL at week 12
Proportion of participants who have ≥5-point reduction in QMG at week 12
Proportion of participants who have a positive PASS at week 12
Proportion of participants who have a 50% MG-ADL total score improvement at week 12

Arms and interventions

Empasiprubart IVExperimental

Participants receive empasiprubart IV in the DBTP

Placebo IVPlacebo comparator

Participants receive placebo IV in the DBTP

Efgartigimod PH20 SC PFSOther

Participants receive open-label efgartigimod PH20 SC PFS in the safety follow-up period

Biologicals: Empasiprubart IV

Other: Placebo IV

Combination products: Efgartigimod PH20 SC PFS

Sites

19 sites in 7 countries

United States 7, Italy 4, Greece 2, Japan 2, Spain 2, Belgium 1, Netherlands 1